Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors

Drug Discovery Today: Disease Models

Volumn 9, Issue 2, 2012, Pages

  Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; AZ 2281; BENZAMIDE DERIVATIVE; BMN 763; CEP 6800; CEP 9722; CISPLATIN; DACARBAZINE; E 7016; GPI 15427; GPI 21016; INIPARIB; INO 1001; IRINOTECAN; KU 58684; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; NU 1085; OLAPARIB; PD 128763; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

AFFINITY CHROMATOGRAPHY; ALLELE; ARTICLE; BRAIN TUMOR; CATALYSIS; CELL VIABILITY; CHEMOSENSITIZATION; COLON CANCER; CRYSTALLIZATION; CYTOPLASM; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DNA STRUCTURE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG POTENTIATION; GASTROINTESTINAL TOXICITY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HYDROGEN BOND; HYPOTENSION; HYPOTHERMIA; IN VITRO STUDY; LOW DRUG DOSE; MELANOMA; MISMATCH REPAIR; NONHUMAN; OVARY CANCER; OXYGENATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACENTA; RADIOSENSITIZATION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THYMUS; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EID: 84862155934     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2012.01.004     Document Type: Review

References (98)

1. de Murcia, G. and Ménissier de Murcia, J. (1994) Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 19, 172-176 (Pubitemid 24115433)
2. Schreiber, V. et al. (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528 (Pubitemid 44036457)
3. Althaus, F.R. et al. (1994) Histone shuttling by PolyADP-ribosylation. Mol. Cell. Biochem. 138 (1/2), 53-59
4. El-Khamisy, S.F. et al. (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 31 (October (19)), 5526-5533 (Pubitemid 37441922)
5. Rouleau, M. et al. (2010) PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301
6. Venkitaraman, A.R. (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182 (Pubitemid 34161138)
7. Shah, G.M. et al. (1995) Methods for biochemical study of poly(ADPribose) metabolism in vitro and in vivo. Anal. Biochem. 227, 1-13
8. Giner, H. et al. (1992) Overproduction and large-scale purification of the human poly(ADP-ribose) polymerase using a baculovirus expression system. Gene 114 (May (2)), 279-283
9. Grube, K. et al. (1991) Direct stimulation of poly(ADP-ribose) polymerase in permeabilised cells by double-stranded DNA oligomers. Anal. Biochem. 193, 236-239
10. Pfieffer, R. et al. (1999) Quantitative nonisotopic immuno-dot-blot method for the assessment cellular poly(ADP-ribosyl)ation capacity. Anal. Biochem. 275, 118-122
11. Jacobson, E.L. and Jacobson, M.K. (1997) Tissue NAD as a biochemical measure of niacin status in humans. Methods Enzymol. 280, 221-230 (Pubitemid 28182358)
12. Durkacz, B.W. et al. (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283, 593-596 (Pubitemid 10136042)
13. Ben-Hur, E. et al. (1985) Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res. 45 (5), 2123-2127 (Pubitemid 15024395)
14. Kelland, L.R. et al. (1988) Differential radiosensitization by the poly(ADPribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 14 (6), 1239-1246
15. Banasik, B. et al. (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl) transferase. J. Biol. Chem. 267, 1569-1575
16. Suto, M.J. et al. (1991) Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase. Anti- Cancer Drug Des. 6, 107-117
17. Boulton, S. et al. (1995) Potentiation of temozolomide cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer 72, 849-856
18. Delaney, C.A. et al. (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6, 2860-2867 (Pubitemid 30482128)
19. Jagtap, P. and Szabo, C. (2005) Poly(ADP-Ribose)polymerase and the therapeautic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421-440 (Pubitemid 40704125)
20. Morrow, D.A. et al. (2009) A randomized, placebocontrolled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADPribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis 27, 359-364
21. Menear, K.A. et al. (2008) 4-[3-(4-Cyclopropanecarbonylpiperazine-1- carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 51, 6581-6591
22. Tentori, L. et al. (2003) Systemic administration of GPI 15427, a novel poly(ADPribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 9, 5370-5379 (Pubitemid 37413592)
23. Donawho, C.K. et al. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728-2737 (Pubitemid 46795129)
24. Plummer, R. et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923
25. Miknyoczki, S.J. et al. (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382
26. Calabrese, C.R. et al. (2003) Identification of potent non-toxic poly(ADPribose) polymerase-1 (PARP-1) inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. 9, 2711-2718 (Pubitemid 36842117)
27. Loh, V.M., Jr et al. (2005) Phthalazinones. Part 1: the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett. 15, 2235-2238 (Pubitemid 40523079)
28. Liu, X. et al. (2008) Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol. Cancer Res. 6 (10), 1621-1629
29. Wedge, S.R. et al. (1996) Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br. J. Cancer 73 (4), 482-490 (Pubitemid 26056467)
30. Curtin, N.J. et al. (2004) Novel PARP-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair deficient cells. Clin. Cancer Res. 10, 881-889 (Pubitemid 38198886)
31. Horton, T.M. et al. (2009) Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukaemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase. Mol. Cancer Ther. 8, 2232-2242
32. Friedman, H.S. et al. (1998) DNA mismatch repair and O-6-alkylguanine- DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 16, 3851-3857 (Pubitemid 29001538)
33. Masutani, M. et al. (2000) The response of Parp knockout mice against DNA damaging agents. Mut. Res. 462, 159-166 (Pubitemid 30190223)
34. Schreiber, V. et al. (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 277 (25), 23028-23036 (Pubitemid 34967289)
35. Tentori, L. et al. (2008) Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur. J. Cancer 44 (9), 1302-1314
36. Dungey, F.A. et al. (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72 (4), 1188-1197
37. Barendsen, G.W. et al. (2001) Importance of cell proliferative state and potentially lethal damage repair on radiation effectiveness: implications for combined tumor treatments. Int. J. Oncol. 19, 247-256
38. Calabrese, C.R. et al. (2004) Preclinical evaluation of a novel poly(ADPribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. JNCI 96, 56-67
39. Mattern, M.R. et al. (1987) Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 47, 1793-1798 (Pubitemid 17056678)
40. Bowman, K.J. et al. (2001) Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity. Br. J. Cancer 84, 106-112 (Pubitemid 32102513)
41. Smith, L.M. et al. (2005) The novel PARP-1 inhibitor, AG14361, sensitises cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 11, 8449-8457 (Pubitemid 41746960)
42. Zhang, Y-W. et al. (2011) Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 39, 3607-3620
43. Boike, G.M. et al. (1990) Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol. Oncol. 38, 315-322 (Pubitemid 20362548)
44. Nguewa, P.A. et al. (2006) Poly(ADP-ribose) polymerase-1 inhibitor 3- aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumour cells. Med. Chem. 2, 47-53 (Pubitemid 44083165)
45. Alaoui-Jamali, M. et al. (1994) Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cisdiaminedichloroplatinum( II) in mammary carcinoma cells resistant to alkylating drugs. Cancer Chemother. Pharmacol. 34, 153-158 (Pubitemid 24157980)
46. Bernges, F. and Zeller, W.J. (1996) Combination effects of poly(ADPribose) polymerase inhibitors and DNA damaging agents in ovarian tumor cell lines - with special reference to cisplatin. J. Cancer Res. Clin. Oncol. 122, 665-670 (Pubitemid 26349019)
47. Guggenheim, E.R. et al. (2008) Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg. Med. Chem. Lett. 16, 10121-10128
48. Evers, B. et al. (2008) Selective inhibition of BRCA-2deficient mammary tumour cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925
49. Bryant, H.E. et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (7035), 913-917 (Pubitemid 40559005)
50. Farmer, H. et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (7035), 917-921 (Pubitemid 40559006)
51. Welcsh, P.L. and King, M.C. (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10, 705-713 (Pubitemid 32331579)
52. Drew, Y. et al. (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 103, 334-346
53. Kennedy, R.D. and D'Andrea, A.D. (2006) DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 24, 3799-3808 (Pubitemid 46622318)
54. McCabe, N. et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (Pubitemid 44299177)
55. Lord, C.J. et al. (2008) A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair 7, 2010-2019
56. Ali, M. et al. (2009) Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin. Cancer Res. 15, 6106-6112
57. Horsman, M.R. (1995) Nicotinamide and other benzamide analogues as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol. 34, 571-587
58. Kaanders, J.H.A.M. et al. (2002) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 3, 728-737 (Pubitemid 35446742)
59. Palma, J.P. et al. (2009) ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumours. Clin. Cancer Res. 15, 7277-7290
60. Albert, J.M. et al. (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13 (3033-3042), 100
61. Barreto-Andrade, J.C. et al. (2011) Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing. Radiation Mol. Cancer Ther. 10 (7), 1185-1193
62. Tentori, L. et al. (2006) Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/ temozolomide efficacy against colon carcinoma. FASEB J. 20 (10), 1709-1711
63. Menissier-de Murcia, J. et al. (1997) Requirement of poly-ADP-ribose. Polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U. S. A. 94, 7303-7307
64. Masutani, M. et al. (1999) Function of poly-ADP-ribose. Polymerase in response to DNA damage: gene-disruption study in mice. Mol. Cell. Biochem. 193, 149-152 (Pubitemid 29176594)
65. Ménissier-de Murcia, J. et al. (2003) Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 22 (9), 2255-2263
66. Shall, S. and de Murcia, G. (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. 460, 1-15 (Pubitemid 30365046)
67. Burkle, A. et al. (2000) Biological significance of poly(ADP- ribosylation) reactions: molecular and genetic approaches. In From DNA Damage and Stress Signalling to Cell Death: Poly ADP-ribosylation Reactions (deMurcia, G. and Shall, S., eds), pp. 80-124, O.U.P.
68. Rottenberg, S. et al. (2008) High sensitivity of BRCA-1 deficient mammary tumours to AZD2281 alone and in combination with platinumdrugs. Proc. Natl. Acad. Sci. U. S. A. 105, 17079-17084
69. Kortmann, U. et al. (2011) Tumor growth inhibition by olaparib in Brca2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17, 783-791
70. Racz, I. et al. (2002) BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumour activity. Biochem. Pharmacol. 63, 1099-1111 (Pubitemid 34267025)
71. Thomas, H.D. et al. (2007) Preclinical selection of a novel poly(ADP-ribose) polymerase (PARP) inhibitor for clinical trial. Mol. Cancer Ther. 6 (3), 945-956 (Pubitemid 46554564)
72. Wang, Z.Q. et al. (1995) Mice lacking ADPRT and poly-ADP-ribosylation develop normally but are susceptible to skin disease. Genes Dev. 9, 509-520
73. Shieh, W.M. et al. (1998) Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J. Biol. Chem. 273 (46), 30069-30072 (Pubitemid 28545464)
74. Hakame, A. et al. (2008) The expanding field of poly(ADP-ribosyl)ation reactions. EMBO Rep. 9, 1094-1100
75. Citaarell, M. et al. (2010) Evolutionalry history of thr poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol. Biol. 10, 308
76. Augustin, A. et al. (2003) PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J. Cell Sci. 116 (Pt 8), 1551-1562 (Pubitemid 36527501)
77. Boehler, C. et al. (2011) Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl. Acad. Sci. U. S. A. 108, 2783-2788
78. Hsiao, S.J. and Smith, S. (2008) Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 90 (1), 83-92 (Pubitemid 350216209)
79. Kickhoefer, V.A. et al. (1999) The 193-kDa vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. 146 (September (5)), 917-928 (Pubitemid 29430436)
80. Chiang, Y.J. et al. (2008) Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development. PLoS One 3 (July (7)), e2639
81. Smith, S. et al. (1998) Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282 (November (5393)), 1484-1487 (Pubitemid 28538609)
82. Gagné, J.P. et al. (2008) Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res. 36 (December (22)), 6959-6976
83. Ruf, A. et al. (1996) Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. U. S. A. 93, 7481-7485 (Pubitemid 26277060)
84. Ruf, A. et al. (1998) Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase) as derived from crystal structures and homology modelling. Biochemistry 37, 3893-3900 (Pubitemid 28162946)
85. Hattori, K. et al. (2004) Rational approaches to discovery of orally active and brainpenetrable quinazolinone inhibitors of poly(ADPribose) polymerase. J. Med. Chem. 47, 4151-4154 (Pubitemid 39045420)
86. Canan Koch, S.S. et al. (2002) Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray co-crystal structure. J. Med. Chem. 45, 4961-4974 (Pubitemid 35278692)
87. Eustermann, S. et al. (2011) The DNA-binding domain of human PARP-1 interacts with DNA single-strand breaks as a monomer through its second zinc finger. J. Mol. Biol. 407 (1), 149-170
88. Lilyestrom, W. et al. (2010) Strudtural and biophysical studies of human PARP-1 in complex with damaged DNA. J. Mol. Biol. 395, 983-994
89. Oliver, A.W. et al. (2004) Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res. 32, 456-464 (Pubitemid 38263036)
90. Ishida, J. et al. (2006) Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modelling. Bioorg. Med. Chem. 14 (March (5)), 1378-1390 (Pubitemid 43120274)
91. Lehtiö, L. et al. (2009) Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52 (May (9)), 3108-3111
92. Karlberg, T. et al. (2010) Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J. Med. Chem. 53 (July (14)), 5352-5355
93. Huang, S.M. et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt ignalling. Nature 461, 614-620
94. Novokov, F.N. et al. (2009) Developing novel approaches to improve binf = ding energy estimation and virtual screening: a PARP case study. J. Mol. Model. 15, 1337-1347
95. Fong, P.C. et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134
96. Fong, P.C. et al. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519
97. Tutt, A. et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244
98. Audeh, M.W. et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244